Event schedules / NPACE 2026 December Virtual Conference: The Final Countdown - Primary Care Updates & AI for APPs

Product Theater: Astellas - Learn About a Nonhormonal FDA-Approved Treatment for Moderate to Severe Vasomotor Symptoms Due to Menopause

Wednesday, December 9, 2026, – (America/New_York)
Product Theater

In this session, we will review an FDA-approved treatment for moderate to severe vasomotor symptoms due to menopause, including indication, mechanism of action, and clinical safety and efficacy.

 

Click here to download the VEOZAHTM (fezolinetant) Prescribing Information

Click here to access the Post Program Survey

For further product information please click here

 

Speakers